Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANGELA HIRA

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1699003509
CMS profile
1366397
Location
RALEIGH, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$1,629.89

82 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,545.89 81
Education $84.00 1

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 82 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANGELA HIRA

NPI 1699003509 · CMS profile ID 1366397

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

RALEIGH, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 82 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1699003509?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANGELA HIRA, NPI 1699003509, CMS profile ID 1366397. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 82 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1699003509?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ANGELA HIRA, NPI 1699003509, CMS profile ID 1366397. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 82 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1699003509?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ANGELA HIRA, NPI 1699003509, CMS profile ID 1366397, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 82 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1699003509?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

82 matching records · $1,629.89 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 82 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 82.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $21.0012/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223866041 CMS
Phathom Pharmaceuticals, Inc. $15.6112/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219275004 CMS
ABBVIE INC. $1.6812/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202048965 CMS
ABBVIE INC. $15.2912/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202048967 CMS
ABBVIE INC. $20.5111/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202048963 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $20.4111/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231800983 CMS
ABBVIE INC. $18.7511/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202048961 CMS
GENZYME CORPORATION $30.8611/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233520683 CMS
Novo Nordisk Inc $16.7811/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188643008 CMS
ABBVIE INC. $15.1411/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202048959 CMS
ABBVIE INC. $17.3311/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202048957 CMS
Janssen Biotech, Inc. $20.6810/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175106213 CMS
ABBVIE INC. $18.1410/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202048955 CMS
ABBVIE INC. $33.2110/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202048953 CMS
GENZYME CORPORATION $19.3810/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233520673 CMS
PFIZER INC. $14.2110/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230723321 CMS
ABBVIE INC. $9.5710/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202048951 CMS
ABBVIE INC. $19.1410/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202048949 CMS
Aimmune Therapeutics, Inc. $21.7510/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249722106 CMS
Janssen Biotech, Inc. $84.0010/14/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1175109057 CMS
ABBVIE INC. $16.0510/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202048947 CMS
Bayer Healthcare Pharmaceuticals Inc. $16.5910/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225576734 CMS
Aimmune Therapeutics, Inc. $21.2410/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249722104 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.1409/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231800978 CMS
Intercept Pharmaceuticals, Inc. $24.5709/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249868633 CMS
Takeda Pharmaceuticals U.S.A., Inc. $16.0409/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223826001 CMS
Aimmune Therapeutics, Inc. $24.3609/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249722108 CMS
Ardelyx, Inc. $19.5009/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247853717 CMS
ABBVIE INC. $18.7609/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202048945 CMS
GENZYME CORPORATION $31.4609/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233520653 CMS
ABBVIE INC. $13.4509/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202048943 CMS
Inspire Medical Systems, Inc. $25.9909/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251473695 CMS
ABBVIE INC. $18.2909/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202048941 CMS
Takeda Pharmaceuticals U.S.A., Inc. $16.8608/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223831796 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $22.4208/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231800973 CMS
ABBVIE INC. $9.9608/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202048939 CMS
Janssen Biotech, Inc. $20.5108/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175109386 CMS
ABBVIE INC. $27.1408/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202048937 CMS
Abbott Laboratories $29.7708/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240824442 CMS
ABBVIE INC. $17.2207/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202048935 CMS
Phathom Pharmaceuticals, Inc. $19.2307/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219275006 CMS
Janssen Biotech, Inc. $24.2007/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175105239 CMS
Lilly USA, LLC $26.2707/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186517381 CMS
Gilead Sciences, Inc. $20.9207/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234518967 CMS
ABBVIE INC. $20.4307/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202048933 CMS
Lilly USA, LLC $21.6506/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186512275 CMS
Intercept Pharmaceuticals, Inc. $19.8406/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249868631 CMS
PFIZER INC. $20.3605/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230151334 CMS
Lilly USA, LLC $20.7205/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186512273 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.8305/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223855829 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $614.45 63
PY2020 $177.83 8
PY2021 $230.60 12
PY2022 $161.61 10
PY2023 $831.68 53
PY2024 $1,507.85 63
PY2025 $1,629.89 82

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $9,187.00 5
PY2024 Principal investigator $47,875.29 13
PY2023 Principal investigator $94,107.04 23
PY2022 Principal investigator $38,177.67 5
PY2021 Principal investigator $119,484.11 29
PY2020 Principal investigator $124,134.00 42
PY2019 Principal investigator $74,432.30 10

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

42 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $385.00 12/15/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721311923
Principal investigator 1 Braintree Laboratories, Inc. $5,374.80 11/23/2020 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC - RALEIGH
BLI4900-301 No dispute reported 06/30/2026 751303915
Principal investigator 1 Allergan, Inc. $1,162.80 11/20/2020 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 721309369
Principal investigator 1 Allergan, Inc. $3,277.50 11/16/2020 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721308271
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $1,500.00 10/28/2020 Non-covered Recipient Entity
M3 WAKE RESEARCH, INC - M3 WR - ERN - PPDS
C3718-301 No dispute reported 06/30/2026 749679813
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $1,500.00 10/28/2020 Non-covered Recipient Entity
M3 WAKE RESEARCH, INC - M3 WR - ERN - PPDS
C3718-301 No dispute reported 06/30/2026 749682077
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $800.00 10/28/2020 Non-covered Recipient Entity
M3 WAKE RESEARCH, INC - M3 WR - ERN - PPDS
C3718-301 No dispute reported 06/30/2026 749684471
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $1,500.00 10/28/2020 Non-covered Recipient Entity
M3 WAKE RESEARCH, INC - M3 WR - ERN - PPDS
C3718-301 No dispute reported 06/30/2026 749686845
Principal investigator 1 Braintree Laboratories, Inc. $1,828.80 10/26/2020 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC - RALEIGH
BLI4900-301 No dispute reported 06/30/2026 751303821
Principal investigator 1 Allergan, Inc. $115.00 10/22/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721304943
Principal investigator 1 Vanda Pharmaceuticals Inc. $2,156.88 10/21/2020 Non-covered Recipient Entity
M3 WAKE RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735128405
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,226.20 09/22/2020 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 737088701
Principal investigator 1 Allergan, Inc. $5,852.00 09/18/2020 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721298663
Principal investigator 1 Allergan, Inc. $435.00 08/27/2020 Non-covered Recipient Entity
WESTERN INSTITUTIONAL REVIEW BOARD
OPEN-LABEL ROLLOVER STUDY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) No dispute reported 06/30/2026 721293825
Principal investigator 1 Allergan, Inc. $1,124.80 08/20/2020 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 721291635
Principal investigator 1 Allergan, Inc. $2,194.25 08/19/2020 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721291419
Principal investigator 1 Vanda Pharmaceuticals Inc. $4,285.62 08/17/2020 Non-covered Recipient Entity
M3 WAKE RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735127755
Principal investigator 1 Allergan, Inc. $405.00 07/30/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721288095
Principal investigator 1 Allergan, Inc. $1,162.80 07/23/2020 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 721287219
Principal investigator 1 Allergan, Inc. $1,971.25 07/20/2020 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721285527
Principal investigator 1 Allergan, Inc. $47.50 06/24/2020 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721281769
Principal investigator 1 Allergan, Inc. $435.00 06/16/2020 Non-covered Recipient Entity
WESTERN INSTITUTIONAL REVIEW BOARD
OPEN-LABEL ROLLOVER STUDY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) No dispute reported 06/30/2026 721279815
Principal investigator 1 Allergan, Inc. $1,058.30 06/02/2020 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 721278487
Principal investigator 1 Allergan, Inc. $1,567.50 05/25/2020 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721276983
Principal investigator 1 Allergan, Inc. $405.00 05/12/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721274239
Principal investigator 1 AbbVie Inc. $9,965.60 04/30/2020 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
M14-431 No dispute reported 06/30/2026 721163901
Principal investigator 1 Adare Pharmaceuticals, Inc. $500.00 04/23/2020 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
Efficacy and Safety APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2) No dispute reported 06/30/2026 750511727
Principal investigator 1 Allergan, Inc. $5,092.00 04/20/2020 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721271453
Principal investigator 1 Vanda Pharmaceuticals Inc. $4,915.50 04/08/2020 Non-covered Recipient Entity
M3 WAKE RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735126091
Principal investigator 1 Braintree Laboratories, Inc. $4,000.00 03/27/2020 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC - RALEIGH
BLI4900-301 No dispute reported 06/30/2026 751303673
Principal investigator 1 Adare Pharmaceuticals, Inc. $6,650.00 03/12/2020 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
Efficacy and Safety APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2) No dispute reported 06/30/2026 750511724
Principal investigator 1 Vanda Pharmaceuticals Inc. $10,110.50 03/11/2020 Non-covered Recipient Entity
M3 WAKE RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735125451
Principal investigator 1 Allergan, Inc. $955.00 03/10/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721263039
Principal investigator 1 Allergan, Inc. $405.00 03/05/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721262099
Principal investigator 1 Allergan, Inc. $1,135.00 02/27/2020 Non-covered Recipient Entity
WESTERN INSTITUTIONAL REVIEW BOARD
OPEN-LABEL ROLLOVER STUDY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) No dispute reported 06/30/2026 721261013
Principal investigator 1 Allergan, Inc. $1,124.80 02/25/2020 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 721260805
Principal investigator 1 Vanda Pharmaceuticals Inc. $1,827.30 02/05/2020 Non-covered Recipient Entity
M3 WAKE RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735124731
Principal investigator 1 Vanda Pharmaceuticals Inc. $19,345.50 02/05/2020 Non-covered Recipient Entity
M3 WAKE RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735124737
Principal investigator 1 Allergan, Inc. $1,025.00 01/30/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721254547
Principal investigator 1 Allergan, Inc. $115.00 01/30/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721254835
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $827.50 01/28/2020 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECTIVE COHORT STUDY COMPARING VEDOLIZUMAB TO OTHER BIOLOGIC AGENTS IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN'S DISEASE No dispute reported 06/30/2026 737068925
Principal investigator 1 Vanda Pharmaceuticals Inc. $12,369.30 01/09/2020 Non-covered Recipient Entity
M3 WAKE RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735124087